The Regulator

Every retail pharmacy that fills Medicare Part D prescriptions could see its network contract terms rewritten under standards the Centers for Medicare and Medicaid Services (CMS) began developing today, following a mandate Congress buried in this year’s government funding law. CMS published a Request for Information (RFI) September 24, 2026 asking the public how it should define “reasonable and relevant” standard contract terms and conditions for Part D network pharmacies, as required by Section 6223(a) of the Consolidated Appropriations Act, 2026, which amended the Social Security Act to bar Part D plan sponsors, in practice the pharmacy benefit managers (PBMs) that run most plans, from excluding any pharmacy willing to meet those standard terms. The RFI asks what documentation should prove compliance, what contracting practices CMS should scrutinize, and what a transparent, objective, enforceable standard should look like; comments are due November 23, 2026, ahead of the requirement taking effect for Part D plan year 2029. Confidence: High. This run reviewed the Federal Register notice directly. Sources: Request for Information; Medicare Part D Reasonable and Relevant Pharmacy Contracting Standards, Federal Register.

The federal government sent more than $45 million to rural Missouri this week, funding building upgrades at 20 hospitals, faster behavioral health consults for rural patients, and training for hundreds of new paramedics. CMS announced the award September 22, 2026 under the Rural Health Transformation Program: $35 million for facility improvements, building upgrades and diagnostic equipment at 20 rural hospital sites, up to $6.4 million to connect rural providers with behavioral health and perinatal specialists for consultations often available within 30 minutes, and up to $4.2 million to train 437 people as emergency medical technicians (EMTs) or paramedics plus retention incentives for rural EMS agencies statewide. The award is part of Missouri’s broader fiscal year 2026 allocation from the $50 billion, 50-state Rural Health Transformation Program CMS created under last year’s reconciliation law. Confidence: High. This run reviewed CMS’s own press release directly. Sources: Trump Administration Announces More Than $45 Million to Upgrade Rural Missouri Hospitals, Connect Families to Rapid Psychiatric Consultations and Maternal Care, and Train More EMS Professionals Across Missouri, Centers for Medicare and Medicaid Services.

Nearly 290,000 Louisiana Medicaid enrollees must pick a new health plan by mid-November after the state’s insurer decided to leave the program entirely. The Louisiana Department of Health (LDH) announced September 1, 2026 that Healthy Blue, owned by Elevance Health, will end its Medicaid managed care contract December 31, 2026; LDH will automatically move remaining members to one of the state’s four other Healthy Louisiana plans starting January 1, 2027, prioritizing family unity and existing doctor relationships, while members can pick their own new plan during a special enrollment period running October 15 through November 16. Multiple outlets have reported Elevance is downsizing its Medicaid business in several states, citing weak profit margins, making Louisiana’s exit part of a wider national pullback as state Medicaid reimbursement rates tighten. Confidence: High. This run reviewed the Louisiana Department of Health’s own announcement directly. Sources: Louisiana Department of Health announces transition for Medicaid Healthy Blue members ahead of contract’s conclusion, Louisiana Department of Health.

The Senate panel that oversees the Food and Drug Administration (FDA) questioned President Trump’s pick to run the agency today, with the chairman himself calling one of her key positions “almost disqualifying.” The Senate Health, Education, Labor and Pensions (HELP) Committee held its confirmation hearing for Dr. Heidi Overton, Trump’s nominee for FDA Commissioner, September 24, 2026; Chairman Bill Cassidy, a physician, said Overton’s support for spacing out childhood vaccines was “almost disqualifying,” while other senators pressed her on past writing critical of the abortion pill mifepristone and her support for tightening its telemedicine and mail-order access. Overton needs a majority of the committee’s 21 members to advance her nomination to a full Senate vote. Confidence: Medium-High. This run reviewed the HELP Committee’s own hearing notice directly; the hearing’s live questioning was not independently observed, relying instead on same-day reporting from NBC News, the Washington Post and the Boston Globe. Sources: Nomination of Heidi Overton to be Commissioner of Food and Drugs, U.S. Senate Committee on Health, Education, Labor and Pensions, Trump’s FDA pick to face scrutiny over abortion pill access at confirmation hearing, NBC News.

Hospitals nationwide are checking their IV bag supplies after the same manufacturer recalled mislabeled saline bags for the third time in 19 months, each recall involving bags that could actually contain concentrated potassium chloride strong enough to kill a patient if injected by mistake. Otsuka ICU Medical LLC recalled one nationwide lot of 0.9 percent Sodium Chloride Injection, USP on September 17, 2026, after a customer complaint found a bag labeled saline actually contained 10 mEq Potassium Chloride Injection inside its overwrap; the recalled lot was distributed nationwide between December 30, 2025 and June 22, 2026. It is the third overwrap mislabeling recall tied to the same 10 mEq potassium chloride product from Otsuka ICU Medical or its predecessor ICU Medical since February 2025; the company has not disclosed whether the incidents share a common cause, no patient injuries have been reported in any of the three recalls, and the FDA had not yet assigned the recall a formal risk classification as of this run. Confidence: Medium-High. This run reviewed the FDA’s own recall notice directly; the three-recall pattern and the lack of an FDA classification were independently corroborated through health-trade reporting. Sources: Otsuka ICU Medical LLC Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection, USP Due To a Product Mix-up with 10 mEq Potassium Chloride Injection, U.S. Food and Drug Administration, Saline Recall Marks Third Potassium Packaging Mix-Up in 19 Months From the Same IV Product Line, Medical Daily.

The FDA barred a convicted counterfeit-goods trafficker from importing any drug into the United States for five years, a reminder of how the agency polices who is allowed to bring medicine across the border. The FDA issued a final debarment order effective September 23, 2026 against Sanjay Kumar, based on his felony conviction for conspiracy to traffic in counterfeit goods; the order bars him from importing or offering to import any drug into the U.S. for five years. Confidence: High. This run reviewed the Federal Register order directly. Sources: Sanjay Kumar: Final Debarment Order, Federal Register.